Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 7/20 | 1.00 |
| ▸ | ADRB1 | P08588 | 5/20 | 1.00 |
| ▸ | ADRB3 | P13945 | 3/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
| ▸ | TP53 | P04637 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 1/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 1/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.97 |
| ▸ | MEN1 | O00255 | 1/20 | 0.97 |
| ▸ | LMNA | P02545 | 1/20 | 0.97 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.97 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.97 |
| ▸ | RXRG | P48443 | 7/20 | 0.44 |
| ▸ | RXRA | P19793 | 6/20 | 0.44 |
| ▸ | RXRB | P28702 | 6/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Zenidolol SCHEMBL29558331 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1ADRB3CYP2D6TSHR | |
| Zenidolol SCHEMBL8027938 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1ADRB3CYP2D6TSHR | |
| Zenidolol SCHEMBL14941581 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1ADRB3CYP2D6TSHR | |
| Zenidolol SCHEMBL15058356 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1ADRB3CYP2D6TSHR | |
| Zenidolol SCHEMBL29387637 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1ADRB3CYP2D6TSHR | |
| Zenidolol SCHEMBL5485188 | 0.99 | ADRB2 (1.00) | ADRB2ADRB1ADRB3CYP2D6TSHR | |
| Zenidolol SCHEMBL29686378 | 0.99 | ADRB2 (1.00) | ADRB2ADRB1ADRB3CYP2D6TSHR | |
| Zenidolol SCHEMBL31074300 | 0.99 | ADRB2 (1.00) | ADRB2ADRB1ADRB3CYP2D6TSHR | |
| SCHEMBL15549338 | 0.85 | ADRB2 (0.74) | ADRB2ADRB1ADRB3CYP2D6TSHR | |
| SCHEMBL11266032 | 0.85 | ADRB2 (0.74) | ADRB2ADRB1ADRB3CYP2D6TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 650 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10788500-B2 | IL1RL-1 as a cardiovascular disease marker and therapeutic target | BRIGHAM & WOMEN'S HOSPITAL, INC. (US) | 2020-09-29 | — | — | US | claimed |
| US-20180217160-A1 | IL1RL-1 as a Cardiovascular Disease Marker and Therapeutic Target | THE BRIGHAM & WOMEN'S HOSPITAL, INC. | 2018-08-02 | — | — | US | claimed |
| EP-3072978-B1 | 1L1RL-1 AS A CARDIOVASCULAR DISEASE MARKER | BRIGHAM & WOMENS HOSPITAL INC (US) | 2018-07-11 | — | — | EP | claimed |
| US-9851362-B2 | 1L1RL-1 as a cardiovascular disease marker and therapeutic target | The Brigham & Women's Hosptial, Inc. (US) | 2017-12-26 | — | — | US | claimed |
| EP-3072978-A1 | 1L1RL-1 AS A CARDIOVASCULAR DISEASE MARKER AND THERAPEUTIC TARGET | The Brigham and Women's Hospital, Inc. (US) | 2016-09-28 | — | — | EP | claimed |
| EP-2336359-B1 | 1L1RL-1 as a cardiovascular disease marker | BRIGHAM & WOMENS HOSPITAL (US) | 2016-04-20 | — | — | EP | claimed |
| US-20150153360-A1 | 1L1RL-1 as a Cardiovascular Disease Marker and Therapeutic Target | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2015-06-04 | — | — | US | claimed |
| US-20140357724-A1 | BETA 2 ADRENOCEPTOR ANTAGONISTS FOR TREATING ORTHOSTATIC HYPOTENSION | INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (US) | 2014-12-04 | — | — | US | claimed |
| WO-2014063189-A1 | METHODS AND PRODUCTS FOR PREVENTING AND/OR TREATING A STRESS INDUCED CARDIOMYOPATHY | ADELAIDE RESEARCH & INNOVATION PTY LTD (AU) | 2014-05-01 | — | — | WO | claimed |
| US-20120244208-A1 | COSMETIC SKIN CARE METHODS AND COMPOSITIONS | de Villiers, Malan (ZA) | 2012-09-27 | — | — | US | claimed |
| EP-0209897-A2 | Peptide enzyme inhibitors | MERCK & CO. INC. (US) | 1987-01-28 | — | — | EP | claimed |
| EP-0163237-A2 | Di- and tri-peptidal renin inhibitors | MERCK & CO. INC. (US) | 1985-12-04 | — | — | EP | claimed |
| EP-0157409-A2 | Renin inhibitors containing 2-substituted statine | MERCK & CO. INC. (US) | 1985-10-09 | — | — | EP | claimed |
| EP-0156318-A2 | C-terminal amide cyclic renin inhibitors containing peptide isosteres | MERCK & CO. INC. (US) | 1985-10-02 | — | — | EP | claimed |
| EP-0156322-A2 | Renin inhibitors containing peptide isosteres | MERCK & CO. INC. (US) | 1985-10-02 | — | — | EP | claimed |
| EP-0129189-A2 | Renin inhibitors containing a C-terminal amide cycle and compositions and combinations containing the same | MERCK & CO. INC. (US) | 1984-12-27 | — | — | EP | claimed |
| EP-0105996-A1 | Ophthalmic compositions for treating elevated intraocular pressure | MERCK & CO. INC. (US) | 1984-04-25 | — | — | EP | claimed |
| EP-0003664-B1 | ALKANOLAMINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1982-02-17 | — | — | EP | claimed |
| US-4275058-A | 1-(7-METHYLINDAN-4-YLOXY)-3-ISOPROPYLAMINOBUTAN-2-OL | IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) | 1981-06-23 | — | — | US | claimed |
| EP-0003664-A1 | Alkanolamine derivatives, process for their preparation and pharmaceutical compositions containing them | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1979-08-22 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140357724-A1 | BETA 2 ADRENOCEPTOR ANTAGONISTS FOR TREATING ORTHOSTATIC HYPOTENSION | ADRB2, ADRA2C, ADRA2A | ADRB2 1/4885ADRB1 6/4885ADRB3 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.